MA50173A - Composés activateurs de bisamide sarcomère et leurs utilisations - Google Patents
Composés activateurs de bisamide sarcomère et leurs utilisationsInfo
- Publication number
- MA50173A MA50173A MA050173A MA50173A MA50173A MA 50173 A MA50173 A MA 50173A MA 050173 A MA050173 A MA 050173A MA 50173 A MA50173 A MA 50173A MA 50173 A MA50173 A MA 50173A
- Authority
- MA
- Morocco
- Prior art keywords
- sarcomeric
- bisamide
- activator compounds
- activator
- compounds
- Prior art date
Links
- 239000012190 activator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- FTQWRYSLUYAIRQ-UHFFFAOYSA-N n-[(octadecanoylamino)methyl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCNC(=O)CCCCCCCCCCCCCCCCC FTQWRYSLUYAIRQ-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762557846P | 2017-09-13 | 2017-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50173A true MA50173A (fr) | 2020-07-29 |
Family
ID=63794635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050173A MA50173A (fr) | 2017-09-13 | 2018-09-13 | Composés activateurs de bisamide sarcomère et leurs utilisations |
Country Status (24)
| Country | Link |
|---|---|
| US (6) | US10723720B2 (OSRAM) |
| EP (1) | EP3681882A1 (OSRAM) |
| JP (1) | JP7308816B2 (OSRAM) |
| KR (1) | KR20200054237A (OSRAM) |
| CN (1) | CN111601798B (OSRAM) |
| AR (1) | AR112804A1 (OSRAM) |
| AU (1) | AU2018332887B2 (OSRAM) |
| BR (1) | BR112020004800A2 (OSRAM) |
| CA (1) | CA3075669A1 (OSRAM) |
| CL (1) | CL2020000610A1 (OSRAM) |
| CO (1) | CO2020002745A2 (OSRAM) |
| CR (1) | CR20200116A (OSRAM) |
| EA (1) | EA202090688A1 (OSRAM) |
| IL (1) | IL272573B2 (OSRAM) |
| JO (1) | JOP20200059A1 (OSRAM) |
| MA (1) | MA50173A (OSRAM) |
| MX (2) | MX2020002696A (OSRAM) |
| PE (1) | PE20200924A1 (OSRAM) |
| PH (1) | PH12020500446A1 (OSRAM) |
| SA (1) | SA520411524B1 (OSRAM) |
| SG (1) | SG11202001377PA (OSRAM) |
| TW (1) | TWI790281B (OSRAM) |
| UY (1) | UY37879A (OSRAM) |
| WO (1) | WO2019055590A1 (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019055590A1 (en) | 2017-09-13 | 2019-03-21 | Amgen Inc. | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| CN117964683A (zh) * | 2018-05-29 | 2024-05-03 | 奥默罗斯公司 | Masp-2抑制剂和使用方法 |
| US20220185791A1 (en) * | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| TWI838482B (zh) * | 2019-03-12 | 2024-04-11 | 美商安進公司 | 心肌肌鈣蛋白活化劑之多晶型物及共晶 |
| CN118496198A (zh) * | 2019-07-23 | 2024-08-16 | 拜耳公司 | 作为农药的新的杂芳基-三唑化合物 |
| JP7737153B2 (ja) | 2019-12-04 | 2025-09-10 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| JP7699389B2 (ja) | 2019-12-04 | 2025-06-27 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| US12030853B2 (en) | 2019-12-04 | 2024-07-09 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| IL293551A (en) | 2019-12-04 | 2022-08-01 | Omeros Corp | 2-masp inhibitor compounds, preparations containing them and their uses |
| MX2022015581A (es) * | 2020-06-17 | 2023-01-24 | Merck Sharp & Dohme Llc | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. |
| IL305835A (en) | 2021-03-15 | 2023-11-01 | Maze Therapeutics Inc | Glycogen synthase 1 (GYS1) inhibitors and methods of using them |
| WO2023122325A2 (en) * | 2021-12-23 | 2023-06-29 | Regents Of The University Of Michigan | Meta anilide compounds and methods for use of the same to treat diseases and disorders |
| AU2024248193A1 (en) | 2023-03-27 | 2025-10-09 | Edgewise Therapeutics, Inc. | Quinolinone amide compounds and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0662529B2 (ja) * | 1984-07-13 | 1994-08-17 | 三共株式会社 | アミノ酸誘導体 |
| US5952307A (en) | 1994-01-21 | 1999-09-14 | Georgia Tech Research Corp. | Basic α-aminoalkylphosphonate derivatives |
| US6306840B1 (en) | 1995-01-23 | 2001-10-23 | Biogen, Inc. | Cell adhesion inhibitors |
| GB9708119D0 (en) | 1997-04-22 | 1997-06-11 | Glaxo Group Ltd | Chemical compounds |
| AU1082901A (en) | 1999-10-18 | 2001-04-30 | National Jewish Medical And Research Center | Method for modulation of cell phenotype |
| US20020002171A1 (en) | 2000-01-28 | 2002-01-03 | Chalquest Richard R. | Materials and methods for killing nematodes and nematode eggs |
| EP1125925A1 (en) | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US6495337B1 (en) | 2000-03-29 | 2002-12-17 | Cytokinetics, Inc. | High throughput sarcomeric assay |
| AU2002237733A1 (en) | 2000-11-07 | 2002-06-18 | Board Of Regents, The University Of Texas System | Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins) |
| US6908923B2 (en) | 2001-12-21 | 2005-06-21 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
| KR20050100615A (ko) | 2003-01-14 | 2005-10-19 | 싸이토키네틱스, 인코포레이티드 | 화합물, 조성물 및 방법 |
| WO2004086865A1 (en) | 2003-03-27 | 2004-10-14 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US20050043260A1 (en) | 2003-04-21 | 2005-02-24 | Baylor College Of Medicine | Wnt as a factor for cardiac myogenesis |
| US7541466B2 (en) | 2003-12-23 | 2009-06-02 | Genzyme Corporation | Tetrahydroisoquinoline derivatives for treating protein trafficking diseases |
| JP2005298628A (ja) | 2004-04-09 | 2005-10-27 | Sumitomo Chemical Co Ltd | オレフィン重合触媒成分及びオレフィン重合体の製造方法 |
| NZ552404A (en) | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| US7538223B2 (en) | 2005-08-04 | 2009-05-26 | Cytokinetics, Inc. | Compounds, compositions and methods |
| EP1959960B1 (en) | 2005-12-15 | 2013-04-10 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| WO2007078815A2 (en) | 2005-12-16 | 2007-07-12 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| WO2007078839A2 (en) | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| WO2007089805A2 (en) | 2006-01-31 | 2007-08-09 | The General Hospital Corporation | Anti-hypertrophic effects and inotropic effects of picot |
| US20080227823A1 (en) | 2007-03-12 | 2008-09-18 | Hassan Pajouhesh | Amide derivatives as calcium channel blockers |
| GB0708818D0 (en) | 2007-05-08 | 2007-06-13 | Portela & Ca Sa | Compounds |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| JP2014534206A (ja) | 2011-10-17 | 2014-12-18 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤 |
| WO2013106646A2 (en) | 2012-01-12 | 2013-07-18 | Yale University | Compounds and methods for the inhibition of vcb e3 ubiquitin ligase |
| EP3608317A1 (en) | 2012-01-12 | 2020-02-12 | Yale University | Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase |
| ES2733340T3 (es) | 2013-03-14 | 2019-11-28 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2015142001A2 (ko) | 2014-03-21 | 2015-09-24 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| JP6712275B2 (ja) | 2015-01-22 | 2020-06-17 | マイオカーディア，インク | 拡張型心筋症（ｄｃｍ）の処置のための４−メチルスルホニル置換ピペリジンウレア化合物 |
| EP3270917A4 (en) | 2015-03-18 | 2018-08-08 | Arvinas, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| US10829440B2 (en) | 2015-06-12 | 2020-11-10 | Brown University | Antibacterial compounds and methods of making and using same |
| KR101766731B1 (ko) | 2015-06-23 | 2017-08-10 | 충남대학교산학협력단 | 강심 활성을 갖는 크로메논 유도체 및 이를 포함하는 심부전의 예방 또는 치료용 약학 조성물 |
| WO2016210240A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AR105809A1 (es) | 2015-08-26 | 2017-11-08 | Achillion Pharmaceuticals Inc | Compuestos para el tratamiento de trastornos médicos |
| KR20160108281A (ko) | 2016-09-06 | 2016-09-19 | 충남대학교산학협력단 | 강심 활성을 갖는 화합물 및 이를 함유하는 심부전 예방 또는 치료용 약학적 조성물 |
| IL270663B (en) | 2017-06-30 | 2022-08-01 | Amgen Inc | Synthesis of omecamtib from carbyl |
| WO2019055590A1 (en) | 2017-09-13 | 2019-03-21 | Amgen Inc. | SARCOMERIC BISAMIDE ACTIVATOR COMPOUNDS AND USES THEREOF |
| ES2815899T3 (es) | 2018-07-09 | 2021-03-31 | Fis Fabbrica Italiana Sintetici Spa | 2-Fluoro-3-nitrotolueno cristalino y procedimiento para la preparación del mismo |
| MX2021001792A (es) | 2018-08-17 | 2021-05-27 | Amgen Inc | Sales y formas cristalinas de omecamtiv mecarbil. |
| WO2020131574A1 (en) | 2018-12-18 | 2020-06-25 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| TWI838482B (zh) | 2019-03-12 | 2024-04-11 | 美商安進公司 | 心肌肌鈣蛋白活化劑之多晶型物及共晶 |
| US20220185791A1 (en) | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
-
2018
- 2018-09-13 WO PCT/US2018/050793 patent/WO2019055590A1/en not_active Ceased
- 2018-09-13 AR ARP180102603A patent/AR112804A1/es unknown
- 2018-09-13 US US16/129,862 patent/US10723720B2/en active Active
- 2018-09-13 JP JP2020514579A patent/JP7308816B2/ja active Active
- 2018-09-13 KR KR1020207010115A patent/KR20200054237A/ko not_active Abandoned
- 2018-09-13 CR CR20200116A patent/CR20200116A/es unknown
- 2018-09-13 PE PE2020000339A patent/PE20200924A1/es unknown
- 2018-09-13 BR BR112020004800-3A patent/BR112020004800A2/pt not_active Application Discontinuation
- 2018-09-13 TW TW107132171A patent/TWI790281B/zh active
- 2018-09-13 SG SG11202001377PA patent/SG11202001377PA/en unknown
- 2018-09-13 CA CA3075669A patent/CA3075669A1/en active Pending
- 2018-09-13 MX MX2020002696A patent/MX2020002696A/es unknown
- 2018-09-13 EP EP18783202.7A patent/EP3681882A1/en not_active Withdrawn
- 2018-09-13 CN CN201880072907.5A patent/CN111601798B/zh active Active
- 2018-09-13 EA EA202090688A patent/EA202090688A1/ru unknown
- 2018-09-13 AU AU2018332887A patent/AU2018332887B2/en active Active
- 2018-09-13 JO JOP/2020/0059A patent/JOP20200059A1/ar unknown
- 2018-09-13 UY UY0001037879A patent/UY37879A/es not_active Application Discontinuation
- 2018-09-13 IL IL272573A patent/IL272573B2/en unknown
- 2018-09-13 MA MA050173A patent/MA50173A/fr unknown
-
2020
- 2020-03-05 PH PH12020500446A patent/PH12020500446A1/en unknown
- 2020-03-10 CL CL2020000610A patent/CL2020000610A1/es unknown
- 2020-03-10 MX MX2022014864A patent/MX2022014864A/es unknown
- 2020-03-10 CO CONC2020/0002745A patent/CO2020002745A2/es unknown
- 2020-03-12 SA SA520411524A patent/SA520411524B1/ar unknown
- 2020-03-27 US US16/833,321 patent/US11254658B2/en active Active
- 2020-03-27 US US16/833,336 patent/US10899746B2/en active Active
- 2020-10-12 US US17/068,518 patent/US11299479B1/en active Active
-
2022
- 2022-02-15 US US17/672,594 patent/US11780826B2/en active Active
-
2023
- 2023-08-17 US US18/451,757 patent/US20240158372A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50173A (fr) | Composés activateurs de bisamide sarcomère et leurs utilisations | |
| MA50256A (fr) | Composés de pyrazolopyrimidinone et leurs utilisations | |
| EP3694861A4 (en) | HETEROCYCLIC COMPOUNDS AND USES THEREOF | |
| EP3917529A4 (en) | Compounds and uses thereof | |
| EP3787607A4 (en) | CAROTINOID COMPOSITIONS AND USES THEREOF | |
| EP3917527A4 (en) | CONNECTIONS AND USES THEREOF | |
| MA52365A (fr) | Composés et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| MA52092A (fr) | Composés et leurs utilisations | |
| EP3337486A4 (en) | DEUTERIZED CONNECTIONS AND USES THEREOF | |
| MA55385A (fr) | Composés et leurs utilisations | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| EP3849983A4 (en) | TRIAZOLEPYRIMIDINE COMPOUNDS AND USES THEREOF | |
| EP3313530A4 (en) | 4,6-PYRIMIDINYLENE DERIVATIVES AND USE THEREOF | |
| EP3790883A4 (en) | Heteroaryl compounds and uses thereof | |
| EP3494119A4 (en) | CONNECTIONS AND COMPOSITIONS AND USES THEREOF | |
| EP3790861A4 (en) | SENOLYTIC COMPOSITIONS AND THEIR USES | |
| EP3838900A4 (en) | 3-ARYLOXY-3-ARYL-PROPYLAMINE COMPOUND AND USES THEREOF | |
| MA48956A (fr) | Composés mic-1 et utilisations associées | |
| EP3450444A4 (en) | CROCINE COMPOUNDS AND USES THEREOF | |
| EP3323817A4 (en) | Aniline pyrimidine derivatives and uses thereof | |
| MA54829A (fr) | Composés et leurs utilisations | |
| MA41495A (fr) | Composés benzoxaborole et leurs utilisations | |
| EP3592430A4 (en) | ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF | |
| EP3856741A4 (en) | POLYMORPHOUS COMPOUNDS AND USES THEREOF |